Overview

imPROving Quality of LIFe In the Long COVID Patient

Status:
Not yet recruiting
Trial end date:
2024-03-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the efficacy of orally administered nirmatrelvir/ritonavir compared with placebo/ritonavir to improve quality of life in non-hospitalized adult participants suffering from post-acute COVID-19 syndrome.
Phase:
Phase 2
Details
Lead Sponsor:
Karolinska Institutet
Collaborators:
Karolinska University Hospital
Pfizer
Treatments:
Ritonavir